Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933727 | 1.00 | ERN1 (1.00) | ERN1KDM4EALDH1A1GAALMNA | |
| SCHEMBL2559703 | 0.83 | ERN1 (0.71) | ERN1KDM4EALDH1A1GAA | |
| SCHEMBL2559706 | 0.83 | ERN1 (0.71) | ERN1KDM4EALDH1A1GAA | |
| SCHEMBL28293621 | 0.81 | ERN1 (0.68) | ERN1KDM4EALDH1A1GAALMNA | |
| SCHEMBL11052763 | 0.81 | ERN1 (0.70) | ERN1LMNAMAPT | |
| SCHEMBL453441 | 0.81 | ERN1 (0.68) | ERN1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL12766841 | 0.80 | ERN1 (1.00) | ERN1 | |
| SCHEMBL1541991 | 0.80 | ERN1 (0.64) | ERN1KDM4EALDH1A1GAALMNA | |
| SCHEMBL6093685 | 0.80 | ERN1 (1.00) | ERN1ALDH1A1 | |
| SCHEMBL8679776 | 0.79 | ERN1 (0.68) | ERN1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619097-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025106477-A1 | NOVEL AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-116211861-B | Active intermediate ZT-1-PVP and preparation method and application thereof | 江苏擎天生物医药有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024107434-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| CN-108299372-B | Medicine for preventing and treating gingivitis and preparation method thereof | 青岛新虹锐泽机械科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3625227-B1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-14 | — | — | EP | disclosed |
| CN-113666812-B | Synthesis method of 5-halogenated veratraldehyde | 四川大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-113735847-B | Synthetic preparation method of berberine hydrochloride | 四川大学 | 2022-06-07 | — | — | CN | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0103173-A1 | Carbamic-acid esters, process and starting material for their preparation, parasiticides containing these esters as active products, as well as the use of such esters and agents in combating parasites | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | ERN1 4299/4885KDM4E 1321/4885ALDH1A1 1254/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | ERN1 1627/4885KDM4E 1089/4885ALDH1A1 477/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ERN1 4404/4885KDM4E 1616/4885ALDH1A1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.